Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
53.1M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
35.7K
-
Shares change
-
+35.7K
-
Total reported value, excl. options
-
$531K
-
Value change
-
+$531K
-
Number of buys
-
2
-
Price
-
$14.89
Significant Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q4 2023
2 filings reported holding ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share as of Q4 2023.
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35.7K shares
of 53.1M outstanding shares and own 0.07% of the company stock.
Largest 10 shareholders include venBio Partners LLC (9.7M shares), FMR LLC (7.47M shares), Vivo Capital, LLC (4.22M shares), Redmile Group, LLC (3.66M shares), Cormorant Asset Management, LP (3.14M shares), ORBIMED ADVISORS LLC (3.1M shares), BlackRock Inc. (2.24M shares), Vestal Point Capital, LP (1.66M shares), VANGUARD GROUP INC (1.5M shares), and MPM BioImpact LLC (1.26M shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.